Short answer
Cullinan Therapeutics, Inc. (CGEM) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$50M
- −2.4% YoY
Source: XBRL data from the Cullinan Therapeutics, Inc. (CGEM) Q1 2026 10-Q on SEC EDGAR. USD.
Cullinan Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; net loss $49.7M vs $48.5M YoY
- Operating margin not applicable; operating loss $53.7M vs $55.0M YoY
- CLN-978 R&D $9.7M, highest product candidate spend; CLN-619 $2.5M, lowest discontinued-program spend
- Cash, equivalents and short-term investments $351.9M; operating cash outflow $46.0M vs $43.2M YoY
- Cash runway at least twelve months; $200.0M ATM equity program established in April 2026
Risk Factors
- Risk Factors section not provided in submitted filing excerpt
- No new, updated, regulatory, operational, competitive, or financial risks identifiable from available text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cullinan Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.